这项研究致力于多模式抗癌药物的开发。我们获得了与类固醇类抗肿瘤药物醋酸阿比特龙缀合的钌配合物，以利用钌和阿比特龙的双重抗肿瘤特性。这些化合物对癌细胞表现出良好的抗增殖活性，并且对原代成纤维细胞具有选择性。实时细胞分析表明，与醋酸阿比特龙相比，化合物二氯(η66-p-伞花烃)(醋酸阿比特龙)钌(II)具有显着的抗增殖活性。关于细胞死亡机制的流式细胞术研究表明，最活跃的化合物比醋酸阿比特龙更有效地诱导细胞凋亡。我们的研究结果证明了这种新型双重作用化合物作为抗癌药物进一步开发的有希望的候选者的潜力。版权所有 © 2024。由爱思唯尔公司出版。

This study is dedicated to the development of multimodal anticancer agents. We have obtained ruthenium complexes conjugated with the steroid-type antitumor drug abiraterone acetate in order to take advantage of the dual antitumor properties of both ruthenium and abiraterone. The compounds exhibit good antiproliferative activity against cancer cells, with selectivity over primary fibroblasts. Real-time cell analysis revealed that compound dichlorido(η66-p-cymene)(abiraterone acetate)ruthenium(II) had pronounced antiproliferation activity compared to abiraterone acetate. Flow cytometric studies on the mechanism of cell death have revealed that the most active compound induces apoptosis more effectively than abiraterone acetate. Our findings demonstrate the potential of this novel dual-action compound as promising candidates for further development as anticancer agents.Copyright © 2024. Published by Elsevier Inc.